Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil
Pulmonary arterial hypertension (PAH) patients have low activity time. Actigraphy provides an objective quantification of movement outside of clinic visits (home, work, social activities). Summary actigraphy measures (total daily steps or activity time) have not been shown to increase after adding t...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | JHLT Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S295013342500014X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856688200941568 |
|---|---|
| author | Daniel Lachant, DO James Gagermeier, MD Scott Seaman, PhD Andrew Wang, MPH Meredith Broderick, PharmD, JD R. James White, MD, PhD |
| author_facet | Daniel Lachant, DO James Gagermeier, MD Scott Seaman, PhD Andrew Wang, MPH Meredith Broderick, PharmD, JD R. James White, MD, PhD |
| author_sort | Daniel Lachant, DO |
| collection | DOAJ |
| description | Pulmonary arterial hypertension (PAH) patients have low activity time. Actigraphy provides an objective quantification of movement outside of clinic visits (home, work, social activities). Summary actigraphy measures (total daily steps or activity time) have not been shown to increase after adding therapies in patients with PAH. We developed a novel treatment responsive metric, Peak Steps, to measure the ‘capacity for movement’ in patients with PAH. Using data from the ADAPT registry (NCT03045029), we calculated Peak Steps and used summary actigraphy measurements and correlated it with six-minute walk distance (6MWD) and emPHasis-10 quality of life scores. After exposure to oral treprostinil, we observed a significant increase in Peak Steps, but no change in total daily steps or activity time. Peak Steps correlated strongly with 6MWD and emPHasis-10 scores. We propose that Peak Steps is a more sensitive marker of treatment response than traditional actigraphy parameters, which can have large behavioral influences. |
| format | Article |
| id | doaj-art-a7ab42cdbf3644988202a966a6cb8b9c |
| institution | Kabale University |
| issn | 2950-1334 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHLT Open |
| spelling | doaj-art-a7ab42cdbf3644988202a966a6cb8b9c2025-02-12T05:33:16ZengElsevierJHLT Open2950-13342025-05-018100219Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinilDaniel Lachant, DO0James Gagermeier, MD1Scott Seaman, PhD2Andrew Wang, MPH3Meredith Broderick, PharmD, JD4R. James White, MD, PhD5Pulmonary & Critical Care Medicine, University of Rochester Medical Center, Rochester, New York; Corresponding author: Daniel Lachant, DO, University of Rochester Medical Center, 601 Elmwood Ave, Box 692, Rochester, NY 14642. Telephone: 585-275-6401.Department of Medicine, Loyola University Medical Center, Maywood, IllinoisUnited Therapeutics Corporation, Research Triangle Park, North CarolinaUnited Therapeutics Corporation, Research Triangle Park, North CarolinaUnited Therapeutics Corporation, Research Triangle Park, North CarolinaPulmonary & Critical Care Medicine, University of Rochester Medical Center, Rochester, New YorkPulmonary arterial hypertension (PAH) patients have low activity time. Actigraphy provides an objective quantification of movement outside of clinic visits (home, work, social activities). Summary actigraphy measures (total daily steps or activity time) have not been shown to increase after adding therapies in patients with PAH. We developed a novel treatment responsive metric, Peak Steps, to measure the ‘capacity for movement’ in patients with PAH. Using data from the ADAPT registry (NCT03045029), we calculated Peak Steps and used summary actigraphy measurements and correlated it with six-minute walk distance (6MWD) and emPHasis-10 quality of life scores. After exposure to oral treprostinil, we observed a significant increase in Peak Steps, but no change in total daily steps or activity time. Peak Steps correlated strongly with 6MWD and emPHasis-10 scores. We propose that Peak Steps is a more sensitive marker of treatment response than traditional actigraphy parameters, which can have large behavioral influences.http://www.sciencedirect.com/science/article/pii/S295013342500014Xpulmonary arterial hypertensionPAHmovementactigraphyoral treprostinilsteps |
| spellingShingle | Daniel Lachant, DO James Gagermeier, MD Scott Seaman, PhD Andrew Wang, MPH Meredith Broderick, PharmD, JD R. James White, MD, PhD Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil JHLT Open pulmonary arterial hypertension PAH movement actigraphy oral treprostinil steps |
| title | Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil |
| title_full | Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil |
| title_fullStr | Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil |
| title_full_unstemmed | Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil |
| title_short | Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil |
| title_sort | peak steps to measure capacity for activity actigraphy in the adapt registry with oral treprostinil |
| topic | pulmonary arterial hypertension PAH movement actigraphy oral treprostinil steps |
| url | http://www.sciencedirect.com/science/article/pii/S295013342500014X |
| work_keys_str_mv | AT daniellachantdo peakstepstomeasurecapacityforactivityactigraphyintheadaptregistrywithoraltreprostinil AT jamesgagermeiermd peakstepstomeasurecapacityforactivityactigraphyintheadaptregistrywithoraltreprostinil AT scottseamanphd peakstepstomeasurecapacityforactivityactigraphyintheadaptregistrywithoraltreprostinil AT andrewwangmph peakstepstomeasurecapacityforactivityactigraphyintheadaptregistrywithoraltreprostinil AT meredithbroderickpharmdjd peakstepstomeasurecapacityforactivityactigraphyintheadaptregistrywithoraltreprostinil AT rjameswhitemdphd peakstepstomeasurecapacityforactivityactigraphyintheadaptregistrywithoraltreprostinil |